JFG
KALV

Jefferies Financial Group’s KalVista Pharmaceuticals KALV Stock Holding History

Jefferies Financial Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-286,046
Closed -$5.76M – 1853
2026
Q1 		$5.76M Buy
+286,046
New +$4.61M 0.04% 319
2025
Q4 		– Sell
-286,875
Closed -$3.49M – 1962
2025
Q3 		$3.49M Buy
+286,875
New +$3.96M 0.02% 461
2025
Q2 		– Sell
-375,000
Closed -$4.33M – 1579
2025
Q1 		$4.33M Hold
375,000
– – 0.04% 333
2024
Q4 		$3.18M Hold
375,000
– – 0.02% 509
2024
Q3 		$4.34M Buy
375,000
+200,000
+114% +$2.52M 0.03% 348
2024
Q2 		$2.06M Buy
175,000
+140,000
+400% +$1.63M 0.02% 540
2024
Q1 		$415K Sell
35,000
-1,045,000
-97% -$13.9M ﹤0.01% 1112
2023
Q4 		$13.2M Buy
1,080,000
+50,000
+5% +$455K 0.09% 170
2023
Q3 		$9.92M Hold
1,030,000
– – 0.09% 170
2023
Q2 		$9.27M Sell
1,030,000
-170,000
-14% -$1.57M 0.08% 218
2023
Q1 		$9.43M Hold
1,200,000
– – 0.08% 221
2022
Q4 		$8.11M Buy
+1,200,000
New +$6.43M 0.06% 264

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Jefferies Financial Group's KALV Position: Q2 2026 in Review

Jefferies Financial Group sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 286,046 shares — an estimated $5.76M sold.

Jefferies Financial Group first reported a position in KALV in Q4 2022 and held it in 12 quarters. The position peaked at $13.2M in Q4 2023. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Jefferies Financial Group reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 286,046 KalVista Pharmaceuticals shares in Q2 2026, an estimated $5.76M.
  • Jefferies Financial Group first reported a position in KalVista Pharmaceuticals in Q4 2022 and held it in 12 quarters.
  • Jefferies Financial Group's KalVista Pharmaceuticals position peaked at $13.2M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.